NCT00282360

Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (planned)
• Sponsor: IRCCS San Raffaele · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Patients with coronary artery disease have an abnormal cardiac metabolism. The hypothesis of this study is that shifting cardiac metabolism from free fatty acids to glucose will improve myocardial ischemia

Detailed description

The present study will evaluate the effect of free fatty acid inhibition with Trimetazidine on silent myocardial ischemia and total ischemic burden in coronary artery disease patients with type II diabetes. Patients will undergo ambulatory ECG monitoring at baseline and will be randomized to receive on top of thei standard anti-anginal therapy trimetazidine or placebo for 6 months. Patients will repeat the ambulatory ECG monitoring at the end of the study

Conditions

• Coronary Artery Disease
• Type II Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Trimetazidine

Timeline

• Start date: 1999-02-01
• Completion: 2003-10-01
• First posted: 2006-01-26
• Last updated: 2006-01-26